Azelaic Acid Gel, 15% recall — Glenmark Pharmaceuticals Inc., Usa (Class II)

Glenmark Pharmaceuticals Inc., Usa is recorded by the U.S. Food and Drug Administration (FDA) as recalling Azelaic Acid Gel, 15% — a Class II recall, initiated 2026-07-23 and posted to the FDA enforcement report on 2026-08-05, under recall number D-0731-2026. Status Ongoing, with no termination date on the record. The reason the FDA record carries is, verbatim: “CGMP Deviations: Product quality complaints concerning abnormal texture or consistency (described as grainy, gritty, or sandy) were received.”. From the product description, the form is gel, the strengths given are 15% and 50 gram, the package is described as 50 gram tubes and it is marked Rx only. 1 National Drug Code number is printed in the record: 68462-626-52. Distribution is recorded as “Nationwide within the United States” — Nationwide (US), with the recalling firm on record in NJ, United States. It is the only recall number the FDA has filed under event ID 99490. Values are reproduced from the linked openFDA report; regulatory information, not medical advice.

Regulatory snapshot

Recall number D-0731-2026
FDA event ID 99490
Classification Class II (intermediate regulatory tier)
Status Ongoing
Recalling firm Glenmark Pharmaceuticals Inc., Usa
Recall initiated 2026-07-23
Reported by FDA 2026-08-05
Report lag 13 days from initiation to report
Distribution Nationwide within the United States. — Nationwide (US)
Firm location on record NJ, United States
Product description (source) Azelaic Acid Gel, 15%, 50 gram tubes, For Topical Use only, Rx only, Distributed by: Glenmark Pharmaceuticals Inc., USA, Elmwood Park, NJ 07407, NDC 68462-626-52.

Reason reported by FDA

CGMP Deviations: Product quality complaints concerning abnormal texture or consistency (described as grainy, gritty, or sandy) were received.

18 words from the enforcement report field reason_for_recall, reproduced without edit — the firm's own wording, not an assessment.

Product identifiers in this record

7 identifying values matched by exact pattern in the 25-word product description above; each is a literal substring of it.

Product named Azelaic Acid Gel
Form Gel
Strength 15% · 50 gram
Package 50 gram tubes
NDC 68462-626-52
Marketing category Rx only
Distributed by Glenmark Pharmaceuticals Inc., USA

Other indexed recalls from Glenmark Pharmaceuticals Inc., Usa

2 indexed records name Glenmark Pharmaceuticals Inc., Usa as the recalling firm, across 2 FDA events, reported 2026-06-24 to 2026-08-05. A coverage-limited activity count over the ingested window, not a quality rating.

Recall recordRecall numberFDA tierStrength / formReported
Alyacen 7/7/7, 0.5mg/0.035mgD-0588-2026Class II0.5mg/0.035mg · Tablets2026-06-24

Reported in the same month (2026-08)

11 enforcement reports carry a report date in 2026-08; these 4 are the Class II ones nearest this record.

Recall recordRecall numberRecalling firmFDA tierReported
Dorzolamide HCl and Timolol Maleate Ophthalmic Solution, 2%/0.5%D-0730-2026Micro Labs Usa IncClass II2026-08-05
Mycophenolate Mofetil for Injection USP, 500 mg/VialD-0734-2026Mylan Pharmaceuticals IncClass II2026-08-05
Dicyclomine Hydrochloride Capsules, 10mgD-0733-2026Aurobindo Pharma Usa IncClass II2026-08-12
Mirabegron Extended-Release Tablets, 25 mgD-0745-2026Zydus Pharmaceuticals (usa) IncClass II2026-08-12

Nearest Class II recalls by date

213 of 250 indexed records share the Class II tier; the 10 nearest to 2026-08-05 by report date are listed here.

Recall recordRecall numberRecalling firmStrength / formReported
Levothyroxine Sodium Tablets, 25 mcgD-0700-2026Major Pharmaceuticals25 mcg · Tablets2026-07-29
Levothyroxine Sodium Tablets, 50 mcgD-0701-2026Major Pharmaceuticals50 mcg · Tablets2026-07-29
Levothyroxine Sodium Tablets, 75 mcgD-0702-2026Major Pharmaceuticals75 mcg · Tablets2026-07-29
Levothyroxine Sodium Tablets, 88 mcgD-0703-2026Major Pharmaceuticals88 mcg · Tablets2026-07-29
Levothyroxine Sodium Tablets, 112 mcgD-0704-2026Major Pharmaceuticals112 mcg · Tablets2026-07-29
Levothyroxine Sodium Tablets, 125 mcgD-0705-2026Major Pharmaceuticals125 mcg · Tablets2026-07-29
Levothyroxine Sodium Tablets, 150 mcgD-0706-2026Major Pharmaceuticals150 mcg · Tablets2026-07-29
Levothyroxine Sodium Tablets, 25 mcgD-0707-2026Major Pharmaceuticals25 mcg · Tablets2026-07-29
Levothyroxine Sodium Tablets, 50 mcgD-0708-2026Major Pharmaceuticals50 mcg · Tablets2026-07-29
Levothyroxine Sodium Tablets, 75 mcgD-0709-2026Major Pharmaceuticals75 mcg · Tablets2026-07-29

Reading this record

Class II is the FDA's own severity tier for the recall action — 213 of the 250 indexed records carry it — and it describes the agency's assessment of the action, not a risk statement about any individual. Match a package against 68462-626-52 at the FDA source to confirm it is covered.

Namespace context: the Class II index (213 records) and the recall hub (250 records, 118 FDA events); Glenmark Pharmaceuticals Inc., Usa (2 indexed records) aggregates this firm across datasets.

Coverage and limits of this record

This page reflects the openFDA enforcement report for D-0731-2026 as ingested on 2026-08-22, which can lag the live FDA record and omits detail held only in primary documents. It offers no clinical assessment, no advice about whether to use any product, and no substitute. For any health question consult a qualified healthcare professional.

Source & provenance

Official source
https://api.fda.gov/drug/enforcement.json?search=recall_number:%22D-0731-2026%22
Source dataset
openFDA Drug Enforcement API
Publication date
2026-08-05
Ingested
2026-08-22
Record hash
c2457c52d8abfe47

Verify every value against the official FDA source above. This site links to the regulator's record rather than replacing it.